Common Contracts
3 similar null contracts by Evolent Health, Inc.
EVOLENT HEALTH, INC. Purchase AgreementEvolent Health, Inc. • December 11th, 2023 • Services-management services • New York
Evolent Health, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $350.0 million principal amount of its 3.50% Convertible Senior Notes due 2029 (the “Firm Securities”) and, at the option of the Initial Purchasers, up to an additional $52.5 million principal amount of its 3.50% Convertible Senior Notes due 2029 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 3.50% Convertible Senior Notes due 2029 granted to the Initial Purchasers in Section 2 hereof. The Firm Securities and the Option Securities are herein referred to as the “Securities.” The Securities will be convertible into shares (the “Underlying Securities”) of Class A common stock of the Company, par value $0.01 per share (the “Class A Common Stock”), cash or a c
EVOLENT HEALTH, INC.Evolent Health, Inc. • October 23rd, 2018 • Services-management services • New York
Evolent Health, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $150.0 million principal amount of its 1.500% Convertible Senior Notes due 2025 (the “Firm Securities”) and, at the option of the Initial Purchasers, up to an additional $22.5 million principal amount of its 1.500% Convertible Senior Notes due 2025 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 1.500% Convertible Senior Notes due 2025 granted to the Initial Purchasers in Section 2 hereof. The Firm Securities and the Option Securities are herein referred to as the “Securities.” The Securities will be convertible into shares (the “Underlying Securities”) of Class A common stock of the Company, par value $0.01 per share (the “Class A Common Stock”). The Secu
EVOLENT HEALTH, INC. Purchase AgreementEvolent Health, Inc. • December 5th, 2016 • Services-management services • New York
Evolent Health, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $110.0 million principal amount of its 2.00% Convertible Senior Notes due 2021 (the “Firm Securities”) and, at the option of the Initial Purchasers, up to an additional $15.0 million principal amount of its 2.00% Convertible Senior Notes due 2021 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 2.00% Convertible Senior Notes due 2021 granted to the Initial Purchasers in Section 2 hereof. The Firm Securities and the Option Securities are herein referred to as the “Securities.” The Securities will be convertible into shares (the “Underlying Securities”) of Class A common stock of the Company, par value $0.01 per share (the “Class A Common Stock”). The Securit
